Chitinase-3-like protein 1 as a predictor for the progression or regression of liver fibrosis

Lin, Biaoyang; Wu, Shengjun; Liu, Yunhua; Liu, Longgen; Mushtaq, Saadiya

doi:10.20517/2394-5079.2018.19

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CHI3L1 is able to activate the Wnt/beta-catenin signal pathway, protein kinase B/AKT, and mitogen-activated protein kinase (MAPK) in macrophage [ 16 ]. As a result, CHI3L1 serves as the signaling molecule in the upstream to regulate liver fibrosis, which may be used to be the prognostic factor for liver fibrosis [ 17 ]. Wang et al have demonstrated there were positive and moderate correlations of CHI3L1 with LSM prior to the treatment ( r = 0.412) as well as following the 78-week treatment ( r = 0.443) among CHB cases.…”

Section: Discussionmentioning

confidence: 99%

Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication

et al. 2020

View full text Add to dashboard Cite

Aim. The success of direct-acting antivirals (DAAs) against hepatitis C virus is a major breakthrough in hepatology. Previous studies have shown that chitinase 3-like protein 1 (CHI3L1) was a marker for staging of liver fibrosis caused by HCV. In this investigation, we used CHI3L1 as a surrogate marker to compare dynamic hepatic fibrosis variations following the elimination of HCV among cases receiving sofosbuvir (SOF)-based regimens and pegylated interferon/ribavirin (PR) treatments. Methods. The study enrolled 105 patients, including 46 SOF-based regimens treated patients, 34 PR-experienced patients, and 25 untreated patients. Serum samples and clinical data were obtained at the baseline, the end of treatment, and at weeks 24 and 48 after treatments. Results. First, we found that serum level of CHI3L1 correlated moderately but significantly with LSM (r=0.615, P<0.001) at the baseline, and diagnosed liver cirrhosis at baseline with high accuracy (AUC=0.939) by ROC analysis. So we explored CHI3L1 as a sensitive biomarker to monitor the regression of liver fibrosis after HCV eradication. We found that the serum CHI3L1 level of CHC cases receiving SOF-based regimen treatments was markedly reduced immediately after treatment compared with that at the baseline (123.79 (118.55) vs. 118.20 (103.68), P=0.001). For cases undergoing PR treatment, the serum CHI3L1 decreased significantly at week 24 posttreatment compared with that at the baseline (69.98 (51.44) vs 89.15 (110.59), P=0.016). For the untreated cirrhotic patients, CHI3L1 levels increased at week 96 follow-up compared with that at the baseline (194.73 (172.46) vs. 89.50 (242.97), P=0.048), reflecting continued worsening of liver fibrosis. Conclusion. CHI3L1 is suggested to be the sensitive marker to monitor fibrosis variations in weeks during treatments and after achieving SVR. It has the potential to allow the identification of early treatment failure for a timely switch to alternative treatment and to allow monitoring progression of fibrosis as a risk factor for liver cirrhosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, CHI3L1 may serve as a non-invasive staging marker for liver fibrosis caused by HBV, HCV, and nonalcoholic fatty liver disease or as a tool to predict the response to antiviral therapy in chronic HBV patients [78]. Also, it has the potential to be used as a novel biomarker for the diagnosis of Gaucher disease, as CHI3L1 levels have been found to be significantly elevated [79].…”

Section: Animal Studiesmentioning

confidence: 99%

The Role of Adipokines in the Pathologies of the Central Nervous System

Huber,

Szerenos,

Lewandowski

et al. 2023

IJMS

View full text Add to dashboard Cite

Adipokines are protein hormones secreted by adipose tissue in response to disruptions in physiological homeostasis within the body’s systems. The regulatory functions of adipokines within the central nervous system (CNS) are multifaceted and intricate, and they have been identified in a number of pathologies. Therefore, specific adipokines have the potential to be used as biomarkers for screening purposes in neurological dysfunctions. The systematic review presented herein focuses on the analysis of the functions of various adipokines in the pathogenesis of CNS diseases. Thirteen proteins were selected for analysis through scientific databases. It was found that these proteins can be identified within the cerebrospinal fluid either by their ability to modify their molecular complex and cross the blood–brain barrier or by being endogenously produced within the CNS itself. As a result, this can correlate with their measurability during pathological processes, including Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis, depression, or brain tumors.

show abstract

Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis

Lin

et al. 2019

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

Chitinase-3-like protein 1 as a predictor for the progression or regression of liver fibrosis

Cited by 3 publications

References 0 publications

Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication

Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication

The Role of Adipokines in the Pathologies of the Central Nervous System

Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis

Contact Info

Product

Resources

About